滤泡淋巴瘤转化的弥漫大B细胞淋巴瘤临床分析

Clinical analysis of diffuse large B-cell lymphoma transformed from follicular lymphoma

目的:探讨滤泡淋巴瘤转化的弥漫大B细胞淋巴瘤患者的临床特征、疗效及预后。方法:收集经病理证实的15例滤泡淋巴瘤转化的弥漫大B细胞淋巴瘤(转化组)及40例原发弥漫大B细胞淋巴瘤(原发组)患者的临床资料进行分析。结果:转化组IPI评分及骨髓侵犯率高于原发组(P均<0.05)。两组均采用CHOP±R方案治疗6周期,转化组完全缓解7例,部分缓解4例,进展4例,原发组分别有27、6、7例,两组疗效差异无统计学意义(Z=1.320,P>0.05)。两组无进展生存及总生存曲线差异有统计学意义(P<0.05),转化组预后差于原发组。结论:滤泡淋巴瘤转化的弥漫大B细胞淋巴瘤预后差于原发弥漫大B细胞淋巴瘤。

Aim:To explore the clinical characteristics,efficacy and prognosis of diffuse large B-cell lymphoma(DLBCL)transformed from follicular lymphoma(FL).Methods:The data of 15 cases of DLBCL transformed from FL(transform group)and 40 primary DLBCL(primary group)patients were collected and analyzed.Results:IPI score and bone marrow involved rate in transform group were higher than those of the primary group(P<0.05).The 2 groups were both treated with CHOP±R regimen for 6 cycles,7,4,4 cases achieved complete response,partial response,and progressive disease in the transform group,which was 27,6,7 cases in the primary group,respectively,and there was no significant difference in the efficacy between the two groups(Z=1.320,P>0.05).There was significant difference in PFS and OS survival curves between the two groups(P<0.05),and the prognosis of the transform group was worse than the primary group.Conclusion:The prognosis of DLBCL transformed from FL is worse than primary DLBCL.